These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28955204)

  • 1. Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications.
    Miguelez C; Benazzouz A; Ugedo L; De Deurwaerdère P
    Front Cell Neurosci; 2017; 11():274. PubMed ID: 28955204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
    Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
    Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
    Navailles S; Bioulac B; Gross C; De Deurwaerdère P
    Neurobiol Dis; 2011 Feb; 41(2):585-90. PubMed ID: 21092759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
    Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease.
    Navailles S; Carta M; Guthrie M; De Deurwaerdère P
    Cent Nerv Syst Agents Med Chem; 2011 Dec; 11(4):305-20. PubMed ID: 22117594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning.
    Chagraoui A; Boulain M; Juvin L; Anouar Y; Barrière G; Deurwaerdère P
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31906250
    [No Abstract]   [Full Text] [Related]  

  • 9. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
    Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
    Nevalainen N; Af Bjerkén S; Gerhardt GA; Strömberg I
    Neuroscience; 2014 Feb; 260():73-86. PubMed ID: 24361918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
    De Deurwaerdère P; Di Giovanni G; Millan MJ
    Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.
    Lanza K; Bishop C
    J Neural Transm (Vienna); 2018 Aug; 125(8):1203-1216. PubMed ID: 29305656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Garcia J; Winkler C; Björklund A; Carta M
    Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
    Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
    J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.
    Sgambato V; Tremblay L
    J Neural Transm (Vienna); 2018 Aug; 125(8):1145-1156. PubMed ID: 29502255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA.
    Gantz SC; Levitt ES; Llamosas N; Neve KA; Williams JT
    Cell Rep; 2015 Aug; 12(6):944-54. PubMed ID: 26235617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.